



## Berkshire West Area Prescribing Committee Policy Statement

<b>Drug Name</b>	Glycopyrronium (Robinul®) and unlicensed preparations
<b>Indication under review</b>	Treatment for hyperhidrosis
<b>Policy No:</b>	APC 014
<b>Date of issue, date reissued:</b>	September 2013, November 2015
<b>Review Date:</b>	November 2018
<b>Policy Statement:</b> Glycopyrronium solution 0.05% is not approved for the treatment of patients with severe palmar and plantar hyperhidrosis, not responding to tap water iontophoresis.	
<b>Traffic Light Status</b>	<b>Brown</b>
<b>Key Points considered:</b> <ul style="list-style-type: none"><li>• Insufficient evidence to demonstrate cost effectiveness of treatment.</li><li>• Secondary care clinicians may use the individual funding route (IFR) for cases where it can be demonstrated that there is true clinical exceptionalty.</li></ul>	
<b>References:</b> <ol style="list-style-type: none"><li>1. eMC. Robinul Powder®. Summary of Product Characteristics. 6/8/2009. Accessed from <a href="http://www.medicines.org.uk/EMC/medicine/22176/SPC/Robinul+Powder/">http://www.medicines.org.uk/EMC/medicine/22176/SPC/Robinul+Powder/</a> on 3/11/2011</li><li>2. Roberts H, Dolianitis C, Sinclair R. Assessing, investigating and managing hyperhidrosis. <i>MedicineToday</i> 2007;8:47-55</li><li>3. Ram R, Lowe NJ, Yamauchi PS. Current and emerging therapeutic modalities for hyperhidrosis, part 1:conservative and noninvasive treatments. <i>Cutis</i> 2007;79:211-7</li><li>4. Thomas I, Brown J, Vafaie J et al. Palmoplantar hyperhidrosis: a therapeutic challenge. <i>American Family Physician</i> 2004;69:1117-21</li><li>5. Lowe NJ, Cliff S, Halford J et al. Guidelines for the primary care treatment and referral of focal hyperhidrosis. Supplement produced in association with Guidelines 2003</li><li>6. Dolianitis C, Scarff CE, Kelly J et al. Iontophoresis with glycopyrrolate for the treatment of palmoplantar hyperhidrosis. <i>Australasian Journal of Dermatology</i> 2004;45:208-12</li></ol>	
<b>Date 1st taken to APC:</b>	4 <sup>th</sup> September 2013
<b>Date re-ratified by GPMOC on behalf of the Board</b>	18 <sup>th</sup> November 2015